SAMHD1 and acute myeloid leukemia: Critically, combinations of ara‐C and non‐allosteric RNRi for AML and other haematological malignancies could be implemented directly in current clinical practice, with SAMHD1 expression being a predictive biomarker for therapeutic efficacy.